Pneumococcal Disease in the Elderly
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 18 (5) , 305-311
- https://doi.org/10.2165/00002512-200118050-00001
Abstract
The effective prevention of Streptococcus pneumoniae infection has a renewed priority in an era in which the emergence of antibacterial-resistant strains has the potential to further compromise efforts to reduce early mortality from invasive pneumococcal infection. Although the 23-valent pneumococcal polysaccharide (PPS) vaccine was approved in the US to prevent respiratory and invasive infection in the elderly and other high-risk populations, the protective efficacy of this vaccine for the growing population of adults aged >65 years remains controversial. The apparent effectiveness of pneumococcal immunisation in clinical studies of elderly adults has varied depending upon whether a reduction in pneumococcal colonisation, pneumonia, bacteraemia or death was used as an outcome. Clinical studies of vaccine efficacy to date suggest that the current pneumococcal vaccine is 56 to 81% effective at preventing invasive pneumococcal infection, and may have additive benefit to influenza vaccine in preventing community-acquired pneumonia, particularly in elderly adults with an increased risk of serious pneumonia requiring hospitalisation. Possible reasons for incomplete protection from pneumococcal infection after immunisation include infection with non-vaccine serotypes, inadequate or ineffective antibody responses, waning of antibody responses, or compromised nonhumoral host defences. Further studies are needed to determine whether: (i) elderly adults who respond poorly to the 23-valent pneumococcal vaccine can be identified prior to immunisation and targeted for study with improved pneumococcal vaccines; (ii) specific nutrient deficiencies can be identified and corrected to improve the immune responsiveness of elderly adults to the PPS vaccine; (iii) newer protein-conjugate or DNA pneumococcal vaccines may be more uniformly immunogenic for elderly adults; and (iv) whether smoking cessation reduces the risk of invasive pneumococcal infection in elderly adults.Keywords
This publication has 48 references indexed in Scilit:
- Antibody response of pneumococcal vaccine: need for booster dosing?International Journal of Antimicrobial Agents, 2000
- Reduction in Functional Antibody Activity Against Streptococcus pneumoniae in Vaccinated Elderly Individuals Highly Correlates with Decreased IgG Antibody AvidityClinical Infectious Diseases, 1999
- Clinical Efficacy of Pneumococcal Vaccine in the ElderlyThe American Journal of Medicine, 1997
- Anti-pneumococcal antibody response in normal subjects: A meta-analysisJournal of Allergy and Clinical Immunology, 1996
- Antibody Response to Pneumococcal Capsular Polysaccharide Vaccine in the ElderlyThe Journal of Infectious Diseases, 1996
- The Lack of Association Between Aging and Postvaccination Levels of IgG Antibody to Capsular Polysaccharides of Streptococcus pneumoniaeClinical Infectious Diseases, 1996
- Antibody to Capsular Polysaccharides of Streptococcus pneumoniae: Prevalence, Persistence, and Response to RevaccinationClinical Infectious Diseases, 1993
- IgG Subclasses of Pneumococcal Antibodies —Effect of Allotype G2m(n)Scandinavian Journal of Immunology, 1989
- Efficacy of Pneumococcal Vaccine in High-Risk PatientsNew England Journal of Medicine, 1986
- Streptococcus pneumoniae Polysaccharide Vaccine: Age and Dose Responses, Safety, Persistence of Antibody, Revaccination, and Simultaneous Administration of Pneumococcal and Influenza VaccinesClinical Infectious Diseases, 1981